第7章 市場環境

第8章 市場分析：投薬経路別

第9章 市場分析：地域別

第10章 市場成長因子

第11章 市場成長因子の影響

第12章 市場課題

第13章 成長因子と課題の影響

第14章 市場動向

戦略的提携・M&A

オフラベル薬剤の利用

R&Dの活発化

第15章 ベンダー情勢

Akorn

Alcon

Allergan

Bausch & Lomb

その他の有力ベンダー

第16章 付録

第17章 Technavioについて

目次

Product Code: IRTNTR8392

About Viral Conjunctivitis Drugs

Viral conjunctivitis, or pink eye, is a type of infectious conjunctivitis that is commonly caused by an adenovirus. Herpes simplex virus (HSV), picornavirus (enterovirus 70, Coxsackie A24), varicella-zoster virus, poxvirus (molluscum contagiosum and vaccinia), and human immunodeficiency virus (HIV) are some of the other viruses that are responsible for the infection. Discomfort through watery discharge is the main symptom of this highly contagious condition. It is often associated with keratoconjunctivitis, which results in slightly blurred vision. No specific treatment option is available for the infection, which heals by itself in 2-3 weeks. Antibiotics and anti-inflammatory drugs are used only if the condition persists. In certain instances, when the infection is serious or persists for weeks, topical antiviral drugs are used. Corneal lesions persist for months even after the condition heals.

Technavio's analysts forecast the global viral conjunctivitis drugs market to grow at a CAGR of 2.41% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global viral conjunctivitis drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of viral conjunctivitis.

The market is divided into the following segments based on geography:

Americas

APAC

EMEA

Technavio's report, Global Viral Conjunctivitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

Akorn

Alcon

Allergan

Bausch & Lomb

Other Prominent Vendors

Adenovir Pharma

Marinomed Biotechnologie

Mediolanum Laboratoires

NanoViricides

Nicox

Novartis

Panoptes Pharma

Rapid Pathogen Screening

Shire

Starpharma

Valeant Pharmaceuticals

Market driver

Rising awareness

For a full, detailed list, view our report

Market challenge

Low diagnosis rate

For a full, detailed list, view our report

Market trend

Use of off-label drugs

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Conjunctivitis

Viral conjunctivitis

Signs and symptoms

Diagnosis

Management

Epidemiology

Economic burden

PART 06: Pipeline analysis

FST-100

APD-209 eye drops

SPL7013

EKC-Cide

PP-001

PART 07: Market landscape

Market overview

Market size and forecast

Viral conjunctivitis drugs market in US

Five forces analysis

PART 08: Market segmentation by route of administration

Topical

Oral

Intravitreal

PART 09: Geographical segmentation

Global viral conjunctivitis drugs market by geography 2015-2020

Viral conjunctivitis drugs market in Americas

Viral conjunctivitis drugs market in EMEA

Viral conjunctivitis drugs market in APAC

PART 10: Market drivers

Rising awareness

Unmet needs for viral conjunctivitis

High prevalence

PART 11: Impact of drivers

PART 12: Market challenges

Low diagnosis rate

Adverse effects and limited efficacy of drugs

Satisfaction with existing therapies

Availability of alternative therapies

PART 13: Impact of drivers and challenges

PART 14: Market trends

Strategic alliances and M&A

Use of off-label drugs

Rise in R&D

PART 15: Vendor landscape

Akorn

Alcon

Allergan

Bausch & Lomb

Other prominent vendors

PART 16: Appendix

List of abbreviations

PART 17: Explore Technavio

List of Exhibits

Exhibit 01: Product offerings

Exhibit 02: Types of conjunctivitis

Exhibit 03: Major types of viral conjunctivitis

Exhibit 04: Signs and symptoms of types of viral conjunctivitis

Exhibit 05: Diagnostic algorithm for viral conjunctivitis

Exhibit 06: Drugs used to treat conjunctivitis

Exhibit 07: Comparison of prevalent rates in different types of conjunctivitis among adults and pediatric population (%)